1. Brownfield bed ramp-up - 156 of 400 beds at Max Smart (Saket) and 116 of 280 at Nanavati-Max are already operational, with the balance due this quarter; commissioned beds are running at \~80% occupancy. These beds are EBITDA-accretive at 39% and 30% unit margins, so completing the handover adds revenue without new fixed-cost drag.
2. CGHS tariff revision - Revised rates effective October 2025 add a net ₹140 crore annually after GST, with super-specialty rates flowing from June 2026 and the run-rate now at ₹140 crore/4 per quarter. At \~85% flow-through to EBITDA, this is roughly 5% of group EBITDA on a base of ₹2,318 crore.
3. Kalinga Hospital turnaround - Acquired 58.28% for ₹298 crore in May 2026, consolidating from Q1 FY27; revenue is ₹19 crore with \~₹2 crore EBITDA at 50% occupancy. Management targets turnaround within 12 months; the 10-acre campus allows expansion to 1,000+ beds, making this the Eastern India entry platform.
4. Gurgaon greenfield commissioning - The 500-bed Sector 56 hospital targets phased commissioning by end FY27, starting with \~200 beds. The Dwarka precedent - breakeven in 6 months against a 1-year guide - suggests this can add \~10% capacity with limited drag.
5. Lucknow (Gomti Nagar) expansion - Adding 100 beds to the existing 468-bed facility over the next two quarters; the unit already does \~5x its acquisition EBITDA at 30%+ margins. The 27-acre campus supports 2,000-2,500 more beds, making this the cheapest organic growth option.
6. Insurance renegotiations - GIPSA and other insurer renewals due September-October 2026, with a 6% automatic price revision already agreed; top 4 insurers contribute \~24-25% of group revenue. A similar resolution in the prior cycle delivered price increases in line with earlier revisions, so this is a recurring, contracted uplift.
7. Medical education - Board in-principle approval for for-profit medical colleges; a 150-seat college needs \~₹300 crore and targets ROCEs above 25-30%, funded from internal accruals. Starting at Lucknow's 27-acre campus leverages existing land and the 12,000-professional MIME training engine.
8. Max@Home and Max Lab - Max@Home revenue ₹78 crore in Q1 FY27, +32% YoY; Max Lab ₹58 crore, +20% YoY. Both are growing at 20-30%+ CAGRs with \~20% and \~16% EBITDA margins respectively, and each new city entry adds a compounding revenue base.
9. International patient expansion - Q1 FY27 international revenue ₹247 crore, +18% YoY, 9% of hospital revenue; ARPOB is \~30% higher than average. With 12 patient assistance centres across 7 countries and a new Tanzania office, this is a high-margin mix shift that needs no capex.